Amgen Inc.
Dual receptor antagonistic antigen-binding proteins and uses thereof
Last updated:
Abstract:
This disclosure related to antagonistic dual receptor antigen-binding proteins, e.g. antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases. The dual receptor antibodies may comprise an antibody to ActRII receptors and may be used to treat pathological condition. The pathological conditions can comprise muscle wasting diseases or any disease that requires stimulation of muscle growth.
Status:
Grant
Type:
Utility
Filling date:
5 Mar 2019
Issue date:
20 Apr 2021